Product Information
IBUPROFEN 100 MG/5 ML SUSP is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $0.0441 per ML under NDC 45802095226. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Sep 23, 2004. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
100 mg/5mL
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802095226
Classification
Generic
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
IBUPROFENApproval Type
Generic (ANDA)
FDA Application
ANDA076925FDA Approved
9/23/2004
TE Code
AB
On Market Since
12/8/2004
Pharmacological Classes
Price Statistics
The NADAC for IBUPROFEN 100 MG/5 ML SUSP has been published 671 times since Nov 28, 2013, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0441 per ML |
|---|---|
| All-time high | $0.0532 (Jun 10, 2015) |
| All-time low | $0.0290 (Jun 22, 2022) |
| 52-week high | $0.0450 |
| 52-week low | $0.0386 |
| Median price | $0.0412 |
| Average price | $0.0417 |
| Largest weekly change | +46.4% (Jul 20, 2022) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 10 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 46% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ibuprofen market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of IBUPROFEN 100 MG/5 ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for IBUPROFEN 100 MG/5 ML SUSP, manufactured by Padagis Israel Pharmaceuticals Ltd, is $0.0441 per ML (NDC 45802095226), effective Sep 30, 2026.
How has the price of IBUPROFEN 100 MG/5 ML SUSP changed over time?
Over the history we have for it, the NADAC for IBUPROFEN 100 MG/5 ML SUSP has held within roughly two percent of its current level. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for IBUPROFEN 100 MG/5 ML SUSP?
Since Nov 28, 2013, the NADAC for IBUPROFEN 100 MG/5 ML SUSP has ranged from a low of $0.0290 (Jun 22, 2022) to a high of $0.0532 (Jun 10, 2015), with a median of $0.0412 per ML.
Are there cheaper alternatives to IBUPROFEN 100 MG/5 ML SUSP?
Yes. 10 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CHILDREN IBUPROFEN 100 MG/5 ML, is $0.0237 per ML — about 46% below IBUPROFEN 100 MG/5 ML SUSP.
Who manufactures IBUPROFEN 100 MG/5 ML SUSP?
IBUPROFEN 100 MG/5 ML SUSP (NDC 45802095226) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.